SCHEMBL3753105

SCHEMBL3753105

O=C(c1ncco1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
FAAH O00519 10/20 0.55
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
TEAD1 P28347 1/20 0.48
SIGMAR1 Q99720 2/20 0.47
HIF1A Q16665 2/20 0.47
EPAS1 Q99814 2/20 0.47
KCNH2 Q12809 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3748226 0.87 FAAH (0.58) FAAH
SCHEMBL3755545 0.87 FAAH (0.56) FAAHSIGMAR1KCNH2
SCHEMBL3747813 0.87 FAAH (0.60) FAAH
SCHEMBL3747939 0.86 FAAH (0.66) FAAH
SCHEMBL3749015 0.86 FAAH (0.55) FAAHTEAD1
SCHEMBL3752384 0.85 FAAH (0.67) FAAHSIGMAR1
SCHEMBL3749375 0.85 FAAH (0.67) FAAH
SCHEMBL3748182 0.85 FAAH (0.66) FAAH
SCHEMBL3753895 0.82 FAAH (0.57) FAAHHRH3
SCHEMBL3747632 0.82 FAAH (0.58) FAAHSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US claimed
EP-2023728-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE Janssen Pharmaceutica, N.V. (BE) 2009-02-18 EP claimed
WO-2007140005-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 WO claimed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
WO-2007140005-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase FAAH, FAAH2, APEH FAAH 1/4885POLB 2215/4885MAPT 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.